Work

Safety and efficacy of daraxonrasib monotherapy as later-line (3L+) treatment for patients (pts) with metastatic pancreatic adenocarcinoma (PDAC).

Year: 2026

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.e15104

Authors: Ignacio Garrido-Laguna, Wungki Park, David S. Hong, Meredith Pelster, Benjamin Herzberg, Alexander I. Spira, Brian A. Mannion, Joel R. Hecht, Salman Rafi Punekar, Aparna Madhukeshwar Hegde, Rashmi Vora, Jenny Yuan, Yidan Xu, Zhaohui Arter, Brian M. Wolpin, David Sommerhalder

Institutions: University of Utah, Huntsman Cancer Institute, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, The University of Texas MD Anderson Cancer Center, Sarah Cannon, Columbia University Irving Medical Center, Columbia University, Virginia Cancer Specialists, Christ Hospital, University of California, Los Angeles, NYU Langone Health, Revolution Medicines (United States), University of California, Irvine, Dana-Farber Cancer Institute

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Revolution Medicines

OpenAlex ID: W7162683357

FWCI:

Cites:

Cited by:

Related to: